Article, 2024

An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity

JOURNAL OF HEADACHE AND PAIN, ISSN 1129-2369, Volume 25, 1, 10.1186/s10194-024-01749-8

Contributors

Griffin, Edward [1] Shirley, Gawain [1] Lee, Xin Ying (Corresponding author) [2] Awad, Susanne F. 0000-0002-5060-7404 [2] Tyagi, Alok 0000-0002-6881-1497 [3] Goadsby, Peter J. [4] [5]

Affiliations

  1. [1] Lundbeck Ltd, Watford, England
    2. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  2. [2] H Lundbeck A S, Copenhagen, Denmark
    3. [NORA names: Lundbeck; Private Research; Denmark; Europe, EU; Nordic; OECD];
  3. [3] NHS Greater Glasgow & Clyde, Glasgow, Scotland
    4. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  4. [4] Kings Coll London, SLaM Biomed Res Ctr, NIHR Kings Clin Res Facil, London, England
    5. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  5. [5] Kings Coll London, SLaM Biomed Res Ctr, NIHR Kings Clin Res Facil, London, England
    6. [NORA names: United Kingdom; Europe, Non-EU; OECD]

Abstract

Abstract not displayed. As this article is not marked as Open Access, it is unclear if we are allowed to show the abstract. Please use the link in the sidebar to view the data provider version of the article including abstract.

Keywords

Anti-CGRP mAbs, Cost-effectiveness, Eptinezumab, Healthcare costs, Migraine, Natural history, Productivity, UK

Data Provider: Clarivate

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+